While Sponsors are gaining experience in protecting individual privacy in Policy 0070 and Health Canada submissions, the CTIS and Eudamed databases will provide a public window to a sponsor’s entire product development life cycle. New reidentification techniques can jeopardise existing practices in anonymisation, while additional privacy regulations, such as the California Consumer Privacy Act, will place new obligations on Sponsors.
The session on Thursday 5 December, chaired by Scott Feiner, will explore these challenges and discuss practical approaches to fulfilling the requirements of the GDPR and individual privacy protection.
Hannah Crowther will be speaking at 3pm, focusing on practical strategies for implementing GDPR across the product development lifecycle.
To find out more information, see the drug information association website.